MAINZ BIOMED (MYNZ) CEO receives 440,000 restricted share grant in Form 4

Rhea-AI Filing Summary

MAINZ BIOMED N.V. reported that Chief Executive Officer Guido Baechler acquired 440,000 Ordinary Shares on February 13, 2026 through a grant of restricted shares under the Mainz Biomed N.V. 2025 Omnibus Incentive Plan, with no cash consideration paid. Following this equity award, his directly held Ordinary Shares increased to 605,058. A footnote adds that 6,362 Ordinary Shares and 158,696 employee stock options had been granted earlier and were previously reported on a prior Form 3.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BAECHLER GUIDO

(Last) (First) (Middle)

MAINZ BIOMED N.V.

ROBERT KOCH STRASSE 50

(Street)

MAINZ 55129

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MAINZ BIOMED N.V. [ MYNZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	02/13/2026		A		440,000	A	$0(1)	605,058(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of restricted shares under Mainz Biomed N.V. 2025 Omnibus Incentive Plan; no cash consideration paid.

2. 6,362 ordinary shares held, and 158,696 employee stock options were granted and previously reported on a Form 3 filed January 26, 2026.

	/s/ Guido Baechler	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MAINZ BIOMED (MYNZ) report for Guido Baechler?

MAINZ BIOMED reported that CEO Guido Baechler received a grant of 440,000 Ordinary Shares on February 13, 2026. These were awarded as restricted shares, increasing his directly held stake to 605,058 Ordinary Shares after the transaction.

Was cash paid for the 440,000-share grant to the MYNZ CEO?

No cash was paid for the 440,000-share grant to the MYNZ CEO. The filing states the award was a grant of restricted shares under the 2025 Omnibus Incentive Plan, explicitly noting that no cash consideration was involved in the transaction.

How many MAINZ BIOMED (MYNZ) shares does the CEO hold after this Form 4?

After this Form 4 transaction, CEO Guido Baechler directly holds 605,058 Ordinary Shares of MAINZ BIOMED. This includes the newly granted 440,000 restricted shares reported in the filing, which were added to his existing directly held equity position.

What equity plan was used for the CEO’s 440,000-share award at MYNZ?

The 440,000-share award to the CEO came from the Mainz Biomed N.V. 2025 Omnibus Incentive Plan. The filing describes the transaction as a grant of restricted shares under this plan, with no cash consideration paid by the reporting person.

Does the MYNZ CEO have other previously reported equity awards?

Yes. A footnote explains that 6,362 Ordinary Shares and 158,696 employee stock options for the MYNZ CEO were granted earlier and disclosed on a prior Form 3 filed January 26, 2026, separate from the new 440,000-share restricted grant.

Is the 440,000-share MYNZ CEO award an open-market purchase?

The 440,000-share award is not an open-market purchase. The Form 4 identifies the transaction as a grant or award acquisition of restricted shares under the company’s 2025 Omnibus Incentive Plan, with a reported price per share of 0.0000.